Immunome (IMNM) Operating Margin: 2023-2025
Historic Operating Margin for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to -1,157.61%.
- Immunome's Operating Margin rose 53482.00% to -1,157.61% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,784.14%, marking a year-over-year increase of 73435.00%. This contributed to the annual value of -3,382.37% for FY2024, which is 260102.00% down from last year.
- Per Immunome's latest filing, its Operating Margin stood at -1,157.61% for Q2 2025, which was up 24.12% from -1,525.50% recorded in Q1 2025.
- Immunome's 5-year Operating Margin high stood at -129.96% for Q3 2023, and its period low was -12,857.05% during Q1 2024.
- Its 3-year average for Operating Margin is -2,492.75%, with a median of -1,608.96% in 2025.
- As far as peak fluctuations go, Immunome's Operating Margin crashed by 1,266,792bps in 2024, and later spiked by 1,133,155bps in 2025.
- Quarterly analysis of 3 years shows Immunome's Operating Margin stood at -2,473.94% in 2023, then plummeted by 55,637bps to -3,030.31% in 2024, then skyrocketed by 53,482bps to -1,157.61% in 2025.
- Its Operating Margin was -1,157.61% in Q2 2025, compared to -1,525.50% in Q1 2025 and -3,030.31% in Q4 2024.